Page 52 - Drug Class Review

Final Report Update 1 Drug Effectiveness Review Project

19. Undertaking systematic reviews of research on effectiveness: Centre for Reviews and
Dissemination; 2001 March. Report No.: 4 (2nd edition).
20. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care. 2nd ed. London: BMJ
Publishing Group; 2001.
21. Ebell M. Does donepezil help patients with moderate Alzheimer's dementia preserve their
ability to function independently? Evidence-Based-Practice 2002.
22. Forette F, Hoover T, Gracon S, de RJ, Hervy, M P, et al. A double-blind, placebo-controlled,
enriched population study of tacrine in patients with Alzheimer's disease. European Journal
of Neurology 1995;2:229-38.
23. Ibach B, Haen E. Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des
2004;10(3):231-51.
24. Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. Tacrine for Alzheimer's
disease. Cochrane Database Syst Rev 2000(3):CD000202.
25. Rogers SL, Doody R, Mohs R, Friedhoff T. E2020 (Aricept TM) improves global and
cognitive function in patients with Alzheimer's Disease. Results of a 30-week trial.
unpublished paper 1996.
26. Salloway S. A double blind randomized pilot study to evaluate the effects of galantamine
and donepezil on sleep and attention and gastrointestinal GI tolerance in patients with mild
to moderate Alzheimer's disease AD. Clinical Trials Journal 2002:1-2.
27. Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, et al. A long-term comparison
of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging
2003;20(10):777-89.
28. Jones RW, Soininen H, Hager K, Aarsland D, Passmore P, Murthy A, et al. A multinational,
randomised, 12-week study comparing the effects of donepezil and galantamine in patients
with mild to moderate Alzheimer's disease. Int J Geriatr Psychiatry 2004;19(1):58-67.
29. Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A
multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in
patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56(6):441-6.
30. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, et al. Efficacy and
safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ
2003;169(6):557-64.
31. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase
inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical
trials. Bmj 2005;331(7512):321-7.
32. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database
Syst Rev 2004(3):CD001190.
33. Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the
symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-
analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry
2004;19(7):624-33.
34. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev
2004(3):CD001747.
35. Schneider LS, Anand R, Farlow MR. Systematic review of the efficacy of rivastigmine for
patients with Alzheimer's disease. International Journal of Geriatric Psychopharmacology
1998;1(Suppl 1):S26-34.

Alzheimer's Drugs Page 52 of 205